Corcept Therapeutics (CORT) Depreciation & Amortization (CF) (2010 - 2026)
Corcept Therapeutics (CORT) reported Depreciation & Amortization (CF) of $598000.0 for Q1 2026, up 29.44% on a YoY basis from $462000.0 in Q1 2025, and up 106.92% sequentially from $289000.0 in Q4 2025.
Corcept Therapeutics (CORT) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Corcept Therapeutics (CORT) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $598000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 29.44% year-over-year to $598000.0; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (up 13.02% YoY), and the FY2025 full-year result was $1.1 million, up 44.53% from the prior year.
- Depreciation & Amortization (CF) climbed to $598000.0 in Q1 2026, from $289000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $660000.0 in Q4 2022 to a low of $76000.0 in Q2 2024.
- A 5-year average of $284882.4 and a median of $281000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) tumbled 94.77% in 2022 and surged 285.0% in 2025, its largest moves.
- Tracing CORT's Depreciation & Amortization (CF) over 5 years: stood at $660000.0 in 2022, then slumped by 67.58% to $214000.0 in 2023, then jumped by 31.31% to $281000.0 in 2024, then grew by 2.85% to $289000.0 in 2025, then surged by 106.92% to $598000.0 in 2026.
- Business Quant data shows CORT's Depreciation & Amortization (CF) at $598000.0 in Q1 2026, $289000.0 in Q4 2025, and $289000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Corcept Therapeutics | 10.09 Bn | 9.76 Bn | 162.02 Mn | 598,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 598,000.00 |
| Mar 31, 2026 | 598,000.00 |
| Dec 31, 2025 | 289,000.00 |
| Dec 31, 2025 | 289,000.00 |
| Sep 30, 2025 | 289,000.00 |
| Sep 30, 2025 | 289,000.00 |
| Jun 30, 2025 | 109,000.00 |
| Jun 30, 2025 | 109,000.00 |
| Mar 31, 2025 | 462,000.00 |
| Mar 31, 2025 | 462,000.00 |
| Dec 31, 2024 | 281,000.00 |
| Dec 31, 2024 | 281,000.00 |
| Sep 30, 2024 | 318,000.00 |
| Sep 30, 2024 | 318,000.00 |
| Jun 30, 2024 | 76,000.00 |
| Jun 30, 2024 | 76,000.00 |
| Mar 31, 2024 | 120,000.00 |
| Mar 31, 2024 | 120,000.00 |
| Dec 31, 2023 | 214,000.00 |
| Dec 31, 2023 | 214,000.00 |